Clinical trials: Rituximab, completed
Nephrotic Syndrome
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome
Open-label, two-parallel-arm, controlled randomized clinical trial testing the superiority of Ofatumumab over Rituximab in maintaining steroid- and calcineurin-inhibitor-free disease remission in SD-INS.
- Trial name
- NCT02394119
- Testing
- Ofatumumab, Rituximab
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Istituto Giannina Gaslini
Rheumatoid Arthritis
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Rituximab, an anti CD-20 monoclonal antibody targeting B lymphocytes is prescribed in rheumatoid arthritis (RA) patients refractory to TNF alpha antagonists.
- Trial name
- LYRITUX (NCT02304354)
- Testing
- Rituximab
- Where
- 8 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Tours
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Non-Hodgkins Lymphoma
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.
- Trial name
- NCT00856245
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Lymphoma, Large B-Cell, Diffuse
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
Patients with primary central nervous system lymphoma (PCNSL) are treated with high-dose-methotrexate-based chemotherapy, which requires hospitalization and extensive expertise to manage related toxicity.
- Trial name
- INGRID (NCT03536039)
- Testing
- NGR-hTNF, RITUXIMAB, Doxorubicin
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Andres J. M. Ferreri
Follicular Lymphoma
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with…
- Trial name
- NCT02187861
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Relapsed Lymphoma
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2…
- Conditions
- Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma
- Trial name
- NCT01742988
- Testing
- fimepinostat, Rituximab, venetoclax
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Curis, Inc.
Rheumatoid Arthritis
Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis
This Phase IV post-marketing, non-interventional, open label, non-comparative and prospective study will examine the efficacy and safety of rituximab in participants who had previously received rituximab in terms of everyday…
- Trial name
- RITAM (NCT02699892)
- Testing
- Rituximab
- Where
- 4 sites in Serbia
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Follicular
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
The primary objective of the study is to assess the pharmacokinetic (PK) similarity of Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients with low tumor burden follicular lymphoma (LTBFL).
- Trial name
- NCT01950273
- Testing
- BI 695500, MabThera
- Where
- 29 sites in Australia, Austria and 11 more
- Volunteers
- 95 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Large-Cell, Diffuse
Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
The aim of the protocol is to compare the outcome of patients with DLBCL stage II bulky, III or IV with 1 to 3 adverse prognostic factors according to the International prognostic index.
- Trial name
- NCT00561379
- Testing
- CHOP+RITUXIMAB, CEEP-RITUXIMAB
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Primary Objective: To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL.
- Trial name
- NCT00794820
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma, Lymphoma
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging…
- Trial name
- NCT00387023
- Testing
- Rituximab, Zevalin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00812669
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 7 sites in Ireland
- Volunteers
- 52 people
- Sponsor
- Cancer Trials Ireland
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01701986
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
ANCA-Associated Vasculitis
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- ADVOCATE (NCT02994927)
- Testing
- Avacopan, Prednisone, Cyclophosphamide
- Where
- 198 sites in United States, Australia and 18 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Scleritis, Orbital Disease
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.
- Trial name
- NCT00415506
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Oregon Health and Science University
Chronic Lymphocytic Leukaemia
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting
- Trial name
- RETRO-idel (NCT03582098)
- Testing
- Idelalisib, Rituximab
- Where
- 16 sites in Ireland, United Kingdom
- Volunteers
- 112 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin
Phase III Copanlisib in Rituximab-refractory iNHL
To assess the safety of copanlisib.
- Trial name
- CHRONOS-2 (NCT02369016)
- Testing
- Copanlisib (BAY 80-6946)
- Where
- 21 sites in Brazil, Bulgaria and 8 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
- Trial name
- NCT06601504
- Testing
- HMPL-760 planned dose 1, R-GemOx, HMPL-760 planned dose 2
- Where
- 16 sites in China
- Volunteers
- 61 people
- Sponsor
- Hutchmed
Lymphoma
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00369681
- Testing
- Bleomycin, Rituximab, Dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.